Market Overview

UPDATE: Merck Q3 Earnings Top Street View

Share:

Merck & Co (NYSE: MRK) reported better-than-expected earnings for the third quarter and narrowed its forecast for the year.

Merck now expects full-year earnings of $3.46 to $3.50 per share, versus its earlier forecast of $3.43 to $3.53 per share. It now projects revenue of $42.4 billion to $42.8 billion.

The Whitehouse Station, New Jersey-based company posted a quarterly profit of $895 million, or $0.31 per share, versus a year-ago profit of $1.12 billion, or $0.38 per share. Excluding certain items, its earnings declined to $0.90 per share from $0.92 per share.

Its revenue slipped 4.3% to $10.56 billion. However, analysts were expecting earnings of $0.88 per share on revenue of $10.64 billion.

Merck's pharmaceutical sales shrank 4% to $9.1 billion, while the animal-health segment's sales climbed 11% to $885 million. Sales for the consumer-care unit dropped 9% to $401 million, while other revenue tumbled 56% to $137 million in the quarter.

The gross margin narrowed to 60.0% from 62.8%.

“Last October, we launched a multi-year initiative to transform Merck and build a platform for sustained, future growth,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “One year later, we delivered solid third-quarter results and are making steady progress in our transformation, including divesting non-core assets, reducing our expense base and investing in our promising new product launches and pipeline.”

The company also received the FDA Breakthrough Therapy Designation for KEYTRUDA in advanced non-small cell lung cancer.

Merck shares rose 0.68% to $58.00 in pre-market trading.

Posted-In: profitEarnings News Guidance

 

Related Articles (MRK)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

pSivida Corp. Receives $25M Milestone Payment

Short Sellers Favor LinkedIn And Pandora Media